{
  "docId": "019de075-2875-74d4-8194-84b6aaf5cb83",
  "docSlug": "17078b9c485724b1d98591e3cd98aa3e",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 60,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2875-74d4-8194-84b6aaf5cb83/13",
  "deckHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83",
  "deckJsonHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83.json",
  "deckAnchorHref": "/decks/019de075-2875-74d4-8194-84b6aaf5cb83#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.235,
        "w": 0.958,
        "x": 0.021,
        "y": 0.152
      },
      "kind": "list",
      "text": "Healthy volunteer SAD and MAD cohorts demonstrated: Robust and sustained IRAK4 degradation in blood and skin with single and multiple daily doses; Broad inhibition of ex vivo TLR-mediated cytokine induction; Generally well tolerated",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ee46a83-b9c3-4096-bb87-97ee8124e7a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.355,
        "w": 0.958,
        "x": 0.021,
        "y": 0.425
      },
      "kind": "list",
      "text": "Patient cohort demonstrated: PK, PD and safety comparable to healthy volunteers; Modest, non-adverse QtcF prolongation spontaneously resolved back to baseline during dosing; Robust IRAK4 degradation in blood and skin associated with systemic anti-inflammatory effect in HS and AD patients, validating pathway and target relevance in HS and AD; Promising clinical activity exceeding benchmark placebo rates and comparing favorably to SOC biologics in both HS and AD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ac2b76b-96df-4846-858d-03f503457410",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.808,
        "x": 0.021,
        "y": 0.855
      },
      "kind": "list",
      "text": "Sanofi has committed to start Ph2 clinical trials, initially in HS and AD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6138feb-c7c2-44b8-a2d8-df6b76b28427",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.522,
        "x": 0.239,
        "y": 0.045
      },
      "kind": "title",
      "text": "Key KT-474 Phase 1 Accomplishments",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b84ed12f-7f19-4a48-bc09-41a9768ac74e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}